Jinwu Financial News | According to the Hong Kong Stock Exchange's disclosure on November 4, Mirxes Holding Company Limited submitted a listing application to the main board of the Hong Kong Stock Exchange, with CCC and CCB International as co-sponsors.
The company is a microribonucleic acid (“miRNA”) technology company originating in Singapore, focusing on popularizing disease screening and diagnostic solutions around the world. As shown in the figure below, as of the last practical date, the company had one core product (i.e. GastroClearTM), two other commercial products (i.e. LungClearTM and FortitudeTM), and six pre-clinical candidate products. The company's core product, GastroClearTM, is a blood-based miRNA test set composed of 12 miRNA biomarkers for gastric cancer screening.
On the financial side, the company's revenue for the six months ended 2021, 2022, 2023, and June 30, 2024 was 60.6498 million (US dollars, same below), 17.759 million, 24.185 million, and 9.5668 million, respectively; during the year/period, the company's equity shareholders were responsible for losses of 3.081 million yuan, 56.6416 million, 69.225 million, and 44.4518 million, respectively million. R&D expenses during the year/period were 7.8821 million, 18.4818 million, 22.6103 million, and 10.6931 million, respectively.
